Paper6975652
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Lotze MT and 4 others. Cancer Res, 1981. Cited by 613 papers, by iCite.
Cite this record
ConductScience Library. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Papers, record 6975652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6975652
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Interleukin-2 | Major topic |
| Lymphokines | Major topic |
| Neoplasms | Major topic |
| T-Lymphocytes | Major topic |
| Adult | |
| Aged | |
| Cells, Cultured | |
| Cytotoxicity, Immunologic | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Osteosarcoma | |
| Time Factors |
Source PubMed
Cited by134
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 613 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42272961 | Adoptive T-cell therapies in the clinic. | Bioeng Transl Med | 2026 | https://conductscience.org/library/papers/42272961 | PubMed |
| 41927344 | Bright side of the dark genome: antigens for next-gen cancer vaccines. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41927344 | PubMed |
| 41707655 | Cell therapy for brain tumors: The first 60 years. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/41707655 | PubMed |
| 41006825 | The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers. | Nat Rev Urol | 2026 | https://conductscience.org/library/papers/41006825 | PubMed |
| 40679708 | Tumor infiltration therapy: from FDA approval to next-generation approaches. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40679708 | PubMed |
| 39126091 | Innate Immune Cells in Melanoma: Implications for Immunotherapy. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39126091 | PubMed |
| 37827864 | IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy. | Trends Immunol | 2023 | https://conductscience.org/library/papers/37827864 | PubMed |
| 36077696 | Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36077696 | PubMed |
| 35821998 | Induction of T Cell Senescence by Cytokine Induced Bystander Activation. | Front Aging | 2021 | https://conductscience.org/library/papers/35821998 | PubMed |
| 35819272 | Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35819272 | PubMed |
| 35314852 | Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. | Nat Rev Drug Discov | 2022 | https://conductscience.org/library/papers/35314852 | PubMed |
| 34937915 | The foundations of immune checkpoint blockade and the ipilimumab approval decennial. | Nat Rev Drug Discov | 2022 | https://conductscience.org/library/papers/34937915 | PubMed |
| 34140957 | Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. | Front Immunol | 2021 | https://conductscience.org/library/papers/34140957 | PubMed |
| 34134616 | Immersion in the search for effective cancer immunotherapies. | Mol Med | 2021 | https://conductscience.org/library/papers/34134616 | PubMed |
| 33723260 | Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. | NPJ Vaccines | 2021 | https://conductscience.org/library/papers/33723260 | PubMed |
| 33407739 | NK cell-based cancer immunotherapy: from basic biology to clinical development. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/33407739 | PubMed |
| 32934330 | Exploring the NK cell platform for cancer immunotherapy. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/32934330 | PubMed |
| 29456568 | Harnessing the immune system in the battle against breast cancer. | Drugs Context | 2018 | https://conductscience.org/library/papers/29456568 | PubMed |
| 29443657 | IL-2 and Beyond in Cancer Immunotherapy. | J Interferon Cytokine Res | 2018 | https://conductscience.org/library/papers/29443657 | PubMed |
| 28491060 | Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. | Front Immunol | 2017 | https://conductscience.org/library/papers/28491060 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6975652
GET https://conductscience.org/api/papers/v1/6975652/cited_by?page=2